All studies
Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional
C5041034 - A Phase 1, Open-Label, Randomized, Single Dose, Crossover Study to Estimate the Relative Bioavailability of Etrasimod (PF-07915503) Mini Tablets in Water and 3 Food Vehicles Compared to the Etrasimod (PF-07915503) Clinical IR Tablets Under Fasted Conditions, and to Evaluate Mini Tablet Palatability in Healthy Adult Participants
At a glance
Status
Ongoing, recruiting
Phase
Human Pharmacology (Phase I)- Other
Sponsor
Pfizer Inc.
Enrolment target
16
Start
12 Jun 2023
What is this study about?
Plasma AUClast, AUCinf and Cmax of etrasimod
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (1)
- —Belgium
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.